Neuromod is a medical technology company that develops and supplies Lenire, the first FDA‑approved bimodal neuromodulation device for treating tinnitus. The device combines sound and mild electrical stimulation to reduce perceived ringing, and Neuromod supports clinics with an all‑in‑one Partner Platform that streamlines onboarding, profitability, and patient care.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic tinnitus have limited therapeutic options, and existing interventions often provide only temporary relief without addressing the underlying neural mechanisms.
Solution
Neuromod offers Lenire, the first FDA‑approved bimodal neuromodulation device that combines acoustic stimulation with mild electrical pulses to retrain auditory pathways and reduce the perception of tinnitus. The system delivers synchronized sound and tongue‑based electrical stimulation through a wearable headset and a tongue electrode, creating neuroplastic changes that diminish tinnitus intensity. Clinical evidence from three large‑scale, peer‑reviewed trials involving over 600 patients demonstrates safety and statistically significant reductions in tinnitus severity. A dedicated Partner Platform supports clinics with streamlined onboarding, practice management tools, and patient‑care workflows, enabling scalable adoption and consistent treatment outcomes. The device is manufactured under a global, redundant supply chain and protected by more than 136 patents across 37 countries, ensuring reliable availability and intellectual‑property protection.
Target Audience
Primary customers are audiologists, otolaryngologists, and tinnitus specialty clinics in the United States and Europe seeking an evidence‑based, reimbursable treatment option for patients with chronic tinnitus.
Features
- Bimodal stimulation protocol that synchronizes acoustic tones with low‑level electrical pulses to the tongue
- FDA‑approved, CE‑marked, ISO‑certified hardware with a compact, patient‑friendly headset and disposable tongue electrode
- Proven efficacy demonstrated in three independent, large‑scale clinical trials (>600 participants) with a >90% clinically significant response rate in real‑world use
- Integrated cloud‑based Partner Platform providing clinic onboarding, treatment scheduling, outcome tracking, and revenue analytics
- End‑to‑end global manufacturing and supply chain with full redundancy to ensure continuous device availability
- Extensive patent portfolio (136+ patents) safeguarding the technology and supporting ongoing innovation